[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Ko ML, Jeng CJ, Huang SH, Shen J, Chen SC, Tzeng CR: Large cell neuroendocrine carcinoma of the uterine cervix associated with adenocarcinoma. Taiwan J Obstet Gynecol; 2007 Mar;46(1):68-70
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the uterine cervix associated with adenocarcinoma.
  • OBJECTIVE: Large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive cervical neoplasm.
  • In the present study, we present a 45-year-old woman with large cell neuroendocrine uterine cervical carcinoma with coexisting adenocarcinoma.
  • On pelvic examination, a polypoid mass of the cervix was discovered.
  • Biopsy of the lesion revealed large cell neuroendocrine carcinoma of the cervix.
  • The patient underwent a radical hysterectomy, and then received concurrent chemotherapy and radiation therapy.
  • She has remained disease free until the time of this writing.
  • CONCLUSION: Patients with LCNEC of the cervix have had poor prognoses; hence aggressive multimodality treatment is recommended.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Neoplasms, Multiple Primary / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Cervix Uteri / pathology. Female. Humans. Middle Aged. Treatment Outcome


2. Li WW, Yau TN, Leung CW, Pong WM, Chan MY: Large-cell neuroendocrine carcinoma of the uterine cervix complicating pregnancy. Hong Kong Med J; 2009 Feb;15(1):69-72
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-cell neuroendocrine carcinoma of the uterine cervix complicating pregnancy.
  • Large-cell neuroendocrine cervical carcinoma is a rare and aggressive cancer that tends to spread and recur early despite intensive multimodal treatment.
  • The optimal mode of therapy is still controversial and management during pregnancy is challenging because foetal well-being must also be considered.
  • We report a patient with clinically stage IIB large-cell neuroendocrine cervical carcinoma who presented with a cervical polyp and vaginal bleeding at 18 weeks of pregnancy.
  • The patient received concurrent chemotherapy and radiation after termination of pregnancy and remained in complete remission 21 months after completion of treatment.


3. Missaoui N, Hmissa S, Trabelsi A, Frappart L, Mokni M, Korbi S: Cervix cancer in Tunisia: clinical and pathological study. Asian Pac J Cancer Prev; 2010;11(1):235-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervix cancer in Tunisia: clinical and pathological study.
  • INTRODUCTION: Uterine cervix cancer is the second most commonly diagnosed cancer among women worldwide.
  • DESIGN: In order to review the clinical and pathological features of cervix cancer in the center of Tunisia, a retrospective study was carried out on 410 cancer cases diagnosed in the Pathology Department, Farhet Hached University Hospital, Sousse, Tunisia (1993-2006).
  • Of the 410 patients, 90.5% had squamous cell carcinoma and 7.3% had adenocarcinoma.
  • Therapy consisted mainly in combination of radiotherapy and surgery in early stages (28.8%), and radiotherapy alone or associated with the chemotherapy in advanced stage (29.7%).
  • Surgery was the only treatment in 29.5% of cases.
  • CONCLUSION: A relatively large proportion of patients presented in stages II to IV, as compared to only 36% with early stages, emphasizing the need to reinforce the early detection of this cancer and its precursor lesions in the center of Tunisia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593963.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


Advertisement
4. Basu P, Biswas J, Mandal R, Choudhury P: Is interferon-alpha and retinoic acid combination along with radiation superior to chemo-radiation in the treatment of advanced carcinoma of cervix? Indian J Cancer; 2006 Apr-Jun;43(2):54-9
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is interferon-alpha and retinoic acid combination along with radiation superior to chemo-radiation in the treatment of advanced carcinoma of cervix?
  • Locally advanced cervical cancers comprise a large majority of the gynecologic cancers in India and other developing countries.
  • In combination with radiation, they substantially enhance the sensitivity of the squamous carcinoma cells to radiation.
  • However, till date, no phase III randomized controlled trial has been done to evaluate this therapeutic modality.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Interferon-alpha / administration & dosage. Tretinoin / administration & dosage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16790941.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Interferon-alpha; 5688UTC01R / Tretinoin
  • [Number-of-references] 26
  •  go-up   go-down


5. Tangjitgamol S, Manusirivithaya S, Choomchuay N, Leelahakorn S, Thawaramara T, Pataradool K, Suekwatana P: Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix. J Obstet Gynaecol Res; 2007 Apr;33(2):218-24
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix.
  • The prognosis of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix is generally poor despite multimodality of treatments.
  • She declined pelvic radiation treatment, so adjuvant chemotherapy (six cycles of paclitaxel/carboplatin) was given for the residual pelvic nodal diseases.
  • Systemic recurrent diseases also showed partial response to the same drug regimen for months with only minimal toxicity.
  • However, she subsequently had progressive diseases in the liver and brain and finally died at 44 months after primary diagnosis and 19 months after recurrent diseases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Paclitaxel / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / secondary. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Fatal Outcome. Female. Humans. Liver Neoplasms / secondary. Neoplasm Recurrence, Local. Ovariectomy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441901.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, Yeger H, Penn LZ: Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res; 2001 Jan;7(1):158-67
Hazardous Substances Data Bank. LOVASTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
  • 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase is the rate-limiting enzyme of the mevalonate pathway, the diverse array of end products of which are vital for a variety of cellular functions, including cholesterol synthesis and cell cycle progression.
  • We showed previously that this enzyme holds a critical role in regulating tumor cell fate, including cell death, as its expression is down-regulated in response to retinoic acid, a potent anticancer therapeutic.
  • We have now extended this work and evaluated a wide variety and large number of tumor-derived cell lines for their sensitivity to lovastatin-induced apoptosis.
  • These cell lines were exposed to a wide range (0-100 microM) of lovastatin for 2 days and assayed for cell viability using the 3,4,5-dimethyl thiazlyl-2,2,5-diphenyltetrazolium bromide assay and the induction of apoptosis by flow cytometric and ultrastructural analyses.
  • Lovastatin induced a pronounced apoptotic response in cells derived from juvenile monomyelocytic leukemia, pediatric solid malignancies (rhabdomyosarcoma and medulloblastoma), and squamous cell carcinoma of the cervix and of the head and neck.
  • The nature of the biologically active form of lovastatin has been challenged recently as the growth-inhibitory effects of this drug were attributed to its prodrug lactone form that does not inhibit HMG-CoA reductase function.
  • Thus, we have identified a subset of tumors that are sensitive to lovastatin-induced apoptosis and show HMG-CoA reductase as a potential therapeutic target of these cancers.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Lovastatin / pharmacology. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Child. Chromatography, High Pressure Liquid. Female. Flow Cytometry. Formazans. Humans. Hydroxymethylglutaryl CoA Reductases / metabolism. Mass Spectrometry. Mevalonic Acid / pharmacology. Microscopy, Electron. Tetrazolium Salts. Tumor Cells, Cultured / cytology. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MEVALONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205904.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Formazans; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Tetrazolium Salts; 23305-68-2 / MTT formazan; 9LHU78OQFD / Lovastatin; EC 1.1.1.- / Hydroxymethylglutaryl CoA Reductases; S5UOB36OCZ / Mevalonic Acid
  •  go-up   go-down


7. Agrawal R: Synchronous dual malignancy: successfully treated cases. J Cancer Res Ther; 2007 Jul-Sep;3(3):153-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathology of cervix showed squamous cell carcinoma (large cell non keratinizing) and clinical stage was IIIB.
  • HPE mastectomy specimen showed infiltrating duct carcinoma and stage II.
  • Patient was treated with external beam radiotherapy for carcinoma cervix and breast simultaneously and chemotherapy as required.
  • HPE brain tissue showed astrocytoma grade II and HPE parotid tumour showed low grade muco-epidermoid carcinoma.
  • Thus it was concluded that patients responded well to treatment.
  • Treatment strategies in case of synchronous double malignancy depend on treating the malignancy that is more advanced first or sometimes both could be treated simultaneously.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Treatment Outcome


8. Chen RJ, Chen KY, Chang TC, Sheu BC, Chow SN, Huang SC: Prognosis and treatment of squamous cell carcinoma from a mature cystic teratoma of the ovary. J Formos Med Assoc; 2008 Nov;107(11):857-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and treatment of squamous cell carcinoma from a mature cystic teratoma of the ovary.
  • BACKGROUND/PURPOSE: Squamous cell carcinoma (SCC) arising from a mature cystic teratoma of the ovary is rare and only reported sporadically.
  • This study assesses the clinical characteristics, treatment, outcome and prognostic factors of reported cases.
  • METHODS: Two hundred and twenty cases from 1976 through to 2005 in MEDLINE were analyzed for patient age, clinical and laboratory data, extent of disease, tumor markers, treatment and survival rates.
  • RESULTS: The disease occurred most often in elderly women (mean, 55.0 +/- 14.4 years) and cysts were large (mean, 13.7 +/- 5.7 cm).
  • Further investigation into treatments for all stages revealed that postoperative adjuvant chemotherapy may produce a better survival rate for both stage III and stage IV cases.
  • Unlike SCCs of the uterine cervix, postoperative adjuvant chemotherapy may produce a better result than adjuvant radiotherapy for advanced-stage cases.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18971155.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Singapore
  • [Number-of-references] 62
  •  go-up   go-down


9. Yamamoto K, Iwahana M, Kumazawa E, Kakihata K, Abe K, Hirano F, Tohgo A, Hoshiai H, Noda K: Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines. Oncol Rep; 2003 May-Jun;10(3):593-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines.
  • Antitumor activity of combination chemotherapy with irinotecan hydrochloride (CPT-11) and nedaplatin was compared to that with CPT-11 and cisplatin.
  • In vitro cytotoxicity of SN-38 (an active metabolite of CPT-11) in combination with nedaplatin or cisplatin was evaluated using three human cervical cancer cell lines (ME-180, CaSki and SiHa).
  • IC50 values of nedaplatin against these three human cervical cancer cell lines were about 2-fold as high as those of cisplatin, indicating somewhat weak cytotoxic effects of nedaplatin.
  • Interactions between two drugs in combination were investigated using a simultaneous-exposure schedule and analyzed by the IC50-based isobologram method.
  • While CPT-11, nedaplatin and cisplatin alone hardly showed any antitumor effects even at the maximum tolerated dose (MTD) levels, the combination chemotherapy with CPT-11 and nedaplatin or cisplatin resulted in significant antitumor effects even at three-quarter MTD of CPT-11 combined with two-third MTD of platinum.
  • All treatments were tolerable for mice, indicating that the combinations did not cause significant enhancement in toxicity.
  • In clinical application, nedaplatin causes a lower incidence of nephropathy and does not require the replacement of a large volume of fluid, which is needed for cisplatin administration, facilitating treatment at the out-patient clinic.
  • These findings suggest that the combination chemotherapy with CPT-11 and nedaplatin for squamous cell cancer of uterine cervix is very useful in clinical practice.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Neoplasms, Experimental / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cell Division / drug effects. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Female. Humans. Inhibitory Concentration 50. Maximum Tolerated Dose. Mice. Mice, Inbred BALB C. Mice, Nude. Organoplatinum Compounds / administration & dosage. Tumor Cells, Cultured


10. Rhemtula H, Grayson W, van Iddekinge B, Tiltman A: Large-cell neuroendocrine carcinoma of the uterine cervix--a clinicopathological study of five cases. S Afr Med J; 2001 Jun;91(6):525-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-cell neuroendocrine carcinoma of the uterine cervix--a clinicopathological study of five cases.
  • OBJECTIVE: The present study describes 5 cases of large-cell neuroendocrine carcinoma (LCNEC) of the uterine cervix, evaluating their clinical features and pathological profiles.
  • A histopathological diagnosis was obtained after biopsy material from all 5 patients was examined microscopically and subjected to immunohistochemical staining with MNF116 (pankeratin) synaptophysin and chromagranin A, all of which are neuroendocrine markers.
  • None of the 5 patients in this series received chemotherapy or underwent surgery.
  • Three of the 5 patients presented with advanced-stage cervical carcinoma, with evidence of metastases in 2 of them.
  • Treatment responses and long-term survival in our series proved to be disappointing as 3 of the 5 patients died in less than 6 months.
  • CONCLUSIONS: LCNECs are rare tumours and distinct from other neoplasms of the uterine cervix.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Parity. Prognosis. Survival Analysis. Synaptophysin. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11455720.001).
  • [ISSN] 0256-9574
  • [Journal-full-title] South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • [ISO-abbreviation] S. Afr. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Synaptophysin
  •  go-up   go-down


11. Sato Y, Shimamoto T, Amada S, Asada Y, Hayashi T: Large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathological study of six cases. Int J Gynecol Pathol; 2003 Jul;22(3):226-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathological study of six cases.
  • Six cases of cervical large cell neuroendocrine carcinomas (LCNEC) were found among 972 patients (0.6%) with invasive cervical carcinoma.
  • All patients underwent radical hysterectomy and received adjuvant chemotherapy and pelvic radiotherapy.
  • On histologic examination, the tumor cells were arranged in an organoid growth pattern and were larger than those of typical small cell carcinoma.
  • The recognition of LCNECs is necessary to establish the most effective treatment for these aggressive tumors.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fallopian Tubes / surgery. Fatal Outcome. Female. Humans. Hysterectomy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Ovariectomy. Papanicolaou Test. Uterine Hemorrhage. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12819387.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kobayashi Y, Akiyama F, Hasumi K: A case of successful pregnancy after treatment of invasive cervical cancer with systemic chemotherapy and conization. Gynecol Oncol; 2006 Jan;100(1):213-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of successful pregnancy after treatment of invasive cervical cancer with systemic chemotherapy and conization.
  • BACKGROUND: The standard therapy for invasive uterine cervical cancer causes loss of the woman's fertility.
  • We report a successful pregnancy in a patient who desired fertility-sparing management of invasive cervical cancer and was treated with systemic chemotherapy and conization.
  • CASE: A 28-year-old nulliparous woman was diagnosed with a large 30-mm-diameter stage IB1 squamous cell carcinoma of the uterine cervix.
  • The patient received 4 courses of systemic chemotherapy with consecutive low-dose BOMP (cisplatin, bleomycin, vincristine and mitomycin C), which produced complete pathological response assessed by examination of specimens from conization.
  • CONCLUSION: This procedure is one method of conservative management to preserve fertility in invasive cervical cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fertility. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Conization. Female. Humans. Mitomycin / administration & dosage. Pregnancy. Pregnancy Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16171850.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 50SG953SK6 / Mitomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin; BOMP protocol
  •  go-up   go-down


13. Conner MG, Richter H, Moran CA, Hameed A, Albores-Saavedra J: Small cell carcinoma of the cervix: a clinicopathologic and immunohistochemical study of 23 cases. Ann Diagn Pathol; 2002 Dec;6(6):345-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the cervix: a clinicopathologic and immunohistochemical study of 23 cases.
  • Twenty-three patients with primary small cell carcinoma of the uterine cervix are presented.
  • Nuclear molding, single cell necrosis, and high mitotic activity were found in all tumors.
  • There was a minor component of large cell neuroendocrine carcinoma in three cases, while foci of adenocarcinoma were identified in two cases.
  • Ten small cell carcinomas were immunoreactive for chromogranin, 13 for synaptophysin, and 10 expressed p53 protein.
  • Treatment modalities included hysterectomy alone or combined with chemotherapy and/or radiation therapy.
  • A few patients received chemotherapy and/or radiation alone.
  • Small cell carcinoma of the cervix is a highly aggressive neoplasm.
  • However, early diagnosis and combined therapeutic modalities may lead to longer survival in some patients.
  • Although the use of immunohistochemistry may be helpful in the diagnosis, small cell carcinoma still remains a morphologic diagnosis.
  • [MeSH-major] Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Biomarkers. Chromogranins / metabolism. Female. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / metabolism. Middle Aged. Synaptophysin / metabolism. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12478483.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / Chromogranins; 0 / Synaptophysin; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins
  •  go-up   go-down


14. Albores-Saavedra J, Martinez-Benitez B, Luevano E: Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis. Int J Gynecol Pathol; 2008 Jul;27(3):333-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis.
  • We report 5 polypoid high-grade neuroendocrine carcinomas of the uterus, 2 small cell carcinomas of the endometrium, and 3 large cell neuroendocrine carcinomas, 2 from the cervix and 1 from the endometrium.
  • The 2 small cell carcinomas of the endometrium arose from and were confined to endometrial polyps, one of which also showed foci of endometrioid adenocarcinoma.
  • The 3 large cell neuroendocrine carcinomas, 2 from the cervix and 1 from the endometrium, were polypoid but did not originate in polyps.
  • All 5 patients were treated by radical hysterectomy and 4 received adjuvant chemotherapy.
  • All patients are alive and disease-free from 9 months to 7 years after treatment (mean survival, 47 months).
  • Two small cell carcinomas and 2 large cell neuroendocrine carcinomas accumulated p53 protein.
  • Two small cell carcinomas and 2 large cell neuroendocrine carcinomas expressed p16.
  • Our findings suggest that stage of disease and a polypoid gross feature are the best predictors for outcome in small cell carcinomas and large cell neuroendocrine carcinomas of the uterus.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Endometrial Neoplasms / pathology. Neuroendocrine Tumors / pathology. Polyps / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580310.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Eifel PJ: Chemoradiation for carcinoma of the cervix: advances and opportunities. Radiat Res; 2000 Sep;154(3):229-36
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation for carcinoma of the cervix: advances and opportunities.
  • Although it is possible to cure many patients with locally advanced cervical cancer using radiation therapy alone, loco-regional relapse continues to be a component of most recurrences.
  • To improve control rates, clinicians have investigated ways of combining chemotherapy and radiation for more than 30 years.
  • Despite encouraging results from phase II trials of neoadjuvant chemotherapy, randomized trials failed to improve on the results with radiation therapy alone.
  • However, recent reports of five large prospective randomized trials demonstrated dramatic improvements in survival and local control rates when cisplatin-containing chemotherapy was given during radiation therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Humans. Hydroxyurea / administration & dosage. Hysterectomy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Mitomycin / administration & dosage. Prospective Studies. Radiation Tolerance. Radiation-Sensitizing Agents / administration & dosage. Randomized Controlled Trials as Topic. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Radiat Res. 2001 Aug;156(2):221-2 [11448246.001]
  • (PMID = 11012341.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 11056-06-7 / Bleomycin; 50SG953SK6 / Mitomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; X6Q56QN5QC / Hydroxyurea; BOMP protocol
  • [Number-of-references] 49
  •  go-up   go-down


16. Ota T, Kitano T, Miyai K, Ogishima D, Yoshida M, Miyake K, Kinoshita K: Small cell carcinoma of the uterine cervix metastasizing to the bone marrow: a case report. J Obstet Gynaecol Res; 2008 Aug;34(4 Pt 2):692-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the uterine cervix metastasizing to the bone marrow: a case report.
  • We report a case of small cell carcinoma (SmCC) of the uterine cervix that metastasized to the bone marrow.
  • A 60-year-old woman with stage IIB SmCC of the cervix was treated with three courses of neoadjuvant chemotherapy followed by radical hysterectomy.
  • Because of the presence of a large residual tumor, the patient underwent postoperative adjuvant chemotherapy.
  • Two months after the last course of chemotherapy, severe pancytopenia developed, and erythroblastic cells were found in the peripheral blood.
  • The patient died of the disease 8 months after the initial diagnosis.
  • This case suggests that SmCC of the cervix can metastasize to bone marrow, that such metastasis can occur in isolation and lead to severe pancytopenia, influencing the clinical course of the disease.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Carcinoma, Small Cell / secondary. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology


17. Trinh XB, Bogers JJ, Van Marck EA, Tjalma WA: Treatment policy of neuroendocrine small cell cancer of the cervix. Eur J Gynaecol Oncol; 2004;25(1):40-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment policy of neuroendocrine small cell cancer of the cervix.
  • Small cell cancers of the cervix are very rare and aggressive tumours.
  • There are no clinical trials, due to their rarity, that would suggest optimal treatment.
  • The present report describes a patient with a neuroendocrine small cell cancer of the cervix Stage IB2 with a positive lymph node.
  • The treatment consisted of radical hysterectomy and node dissection, adjuvant chemotherapy, chemoradiation and brachytherapy.
  • Since 1996, there has been a classification for neuroendocrine tumours (NETs) of the cervix in four categories (large cell, small cell, typical carcinoid and atypical carcinoid).
  • The aggressive behaviour of neuroendocrine small cell cancer is demonstrated by the high percentage of early lymphatic node and vessel invasion (68 and 90%).
  • Multimodal therapy for these tumours appears to give good response but often implies severe side-effects.
  • [MeSH-major] Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / therapy. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Decision Trees. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Neoplasm Staging


18. Niwa K, Nonaka-Shibata M, Satoh E, Hirose Y: Cervical large cell neuroendocrine carcinoma with cytologic presentation: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):977-80
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical large cell neuroendocrine carcinoma with cytologic presentation: a case report.
  • BACKGROUND: Large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive cervical neoplasm.
  • The cervical smears showed cells dispersed as single cells or arranged as loosely cohesive sheets or glandlike aggregate and the nuclear size was almost 3-5 times larger than that of small lymphocytes.
  • The patient underwent a radical hysterectomy and then received radiation and systemic chemotherapy.
  • CONCLUSION: Cytologic and colposcopic findings for LCNEC of the uterine cervix are reported.
  • Early diagnosis of the tumor is important.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Nucleus / pathology. Colposcopy. Fatal Outcome. Female. Humans

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053581.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Eifel PJ, Moughan J, Erickson B, Iarocci T, Grant D, Owen J: Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study. Int J Radiat Oncol Biol Phys; 2004 Nov 15;60(4):1144-53
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study.
  • PURPOSE: To determine the influence of research findings and evolving technology on the practice of radiotherapy in patients with carcinoma of the cervix.
  • Most estimates were based on the 383 patients who had received their initial therapy at a surveyed facility (excluding the 59 patients who were referred for brachytherapy only after initial treatment at another facility).
  • Patients treated at small facilities were significantly more likely to have received a total dose to Point A of <80 Gy, to have had their treatment protracted to >70 days, and to have undergone adjuvant hysterectomy or chemotherapy.
  • In large facilities, radiotherapy was less likely to be protracted to >70 days in the 1996-1999 survey than in the 1992-1994 survey (p < 0.0001); however, in small facilities, treatment was more likely to be protracted than in the earlier survey (p = 0.06), contributing to increasing disparities between the treatments given in large and small facilities.
  • The proportion of patients receiving chemotherapy as part of their initial treatment in 1996-1999 (34.6%) was not significantly different statistically from that in 1992-1994 (25.6%; p = 0.3).
  • However, in 1999, 63% of patients had received chemotherapy compared with 19%, 28%, and 26% in 1996, 1997, and 1998, respectively.
  • The details and confirmation of chemotherapy administration were rarely documented in the radiation oncology clinic notes and hospital records.
  • CONCLUSION: The sharp increase in the use of chemotherapy in 1999 suggested rapid application of the results from randomized trials.
  • The practice at small facilities appears to differ significantly from that at larger facilities in several respects, with a statistically significantly larger proportion of treatments at small facilities failing to meet current guidelines for optimal treatment.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Antineoplastic Agents / therapeutic use. Brachytherapy / trends. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Female. Humans. Hysterectomy. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15519786.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 56435
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Erhan Y, Dikmen Y, Yucebilgin MS, Zekioglu O, Mgoyi L, Terek MC: Large cell neuroendocrine carcinoma of the uterine corpus metastatic to brain and lung: case report and review of the literature. Eur J Gynaecol Oncol; 2004;25(1):109-12
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the uterine corpus metastatic to brain and lung: case report and review of the literature.
  • Neuroendocrine carcinoma of the uterine corpus is a rare aggressive tumor with a similar unfavorable outcome to that of the cervix.
  • The large cell type is considerably rarer than the small cell neuroendocrine carcinoma of the uterine corpus.
  • We report a case of a 52-year-old woman who presented with a large cell neuroendocrine tumor of the uterine corpus with very aggressive clinical behavior, cerebral and pulmonary metastases six and four months after initial diagnosis and adjuvant radiotherapy, respectively.
  • Despite successful surgical extirpation of the cerebral metastatic lesion she did not respond to chemotherapy and died four months after disease recurrence.
  • [MeSH-major] Brain Neoplasms / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Lung Neoplasms / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15053077.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 31
  •  go-up   go-down


21. Steed HL, Pearcey RG, Capstick V, Honore LH: Invasive squamous cell carcinoma of the vagina during pregnancy. Obstet Gynecol; 2002 Nov;100(5 Pt 2):1105-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive squamous cell carcinoma of the vagina during pregnancy.
  • BACKGROUND: Squamous cell carcinoma of the vagina in pregnancy is rare.
  • CASE: A 28-year-old primigravida with antepartum bleeding at 20 weeks' gestation was diagnosed with squamous cell carcinoma after biopsy of a vaginal mass.
  • The histology revealed an invasive grade 3 squamous cell carcinoma of large-cell, nonkeratinizing type.
  • The patient declined pregnancy termination and immediate radiation treatment.
  • A decision was made in consultation with the neonatal unit to deliver her at 32 weeks' gestation.
  • After corticosteroid treatment, she was delivered by cesarean delivery.
  • Postoperatively, she received external beam radiation and brachytherapy and concurrent cisplatin chemotherapy.
  • She is disease free 3 years from her original diagnosis.
  • CONCLUSION: This case emphasizes the importance of a thorough pelvic examination to assess the vaginal walls and cervix at the first prenatal visit and with any antepartum bleeding episode.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Pregnancy Complications, Neoplastic / pathology. Pregnancy Complications, Neoplastic / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adult. Brachytherapy. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Pregnancy. Radiotherapy Dosage


22. Brown KR, Leitao MM Jr: Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature. Eur J Gynaecol Oncol; 2010;31(1):107-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.
  • We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Neuroendocrine / drug therapy. Cisplatin / adverse effects. Inappropriate ADH Syndrome / chemically induced. Uterine Cervical Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349794.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Malzoni M, Spina V, Perniola G, Aleandri V, Mossa B, Iuele T, Imperato F: Laparoscopic surgery in treatment of stage IIb cervical cancer after neoadjuvant chemotherapy. A case report and review of the literature. Eur J Gynaecol Oncol; 2003;24(5):393-7
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery in treatment of stage IIb cervical cancer after neoadjuvant chemotherapy. A case report and review of the literature.
  • BACKGROUND: A detailed operative procedure of laparoscopic radical hysterectomy (type III) with pelvic and aortic lymphadenectomy after neoadjuvant chemoterapy in treatment of Stage IIb cervical cancer is described.
  • CASE REPORT: A 50-year-old patient with Stage IIb squamous cell carcinoma of the uterine cervix, who initially was not surgically resectable, received three courses of neoadjuvant chemotherapy that included ifosfamide 5 g/m2, cisplatin 50 mg/m2 and paclitaxel 175 mg/m2 (TIP).
  • Following a partial clinical response to chemotherapy, the patient underwent laparoscopic type III radical hysterectomy with bilateral salpingo-oophorectomy and pelvic and paraaortic lymphadenectomy.
  • The surgical procedure lasted 250 minutes.
  • The patient also underwent adjuvant radiation therapy.
  • CONCLUSIONS: This experience suggests that such a surgical procedure is safe.
  • Large studies with long term follow-up are needed to confirm that this approach may be proposed as an alternative to conventional surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Laparoscopy. Neoadjuvant Therapy. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14584654.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


24. Harvey RL, Mychaskiw G 2nd, Sachdev V, Heath BJ: Isolated cardiac metastasis of cervical carcinoma presenting as disseminated intravascular coagulopathy. A case report. J Reprod Med; 2000 Jul;45(7):603-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated cardiac metastasis of cervical carcinoma presenting as disseminated intravascular coagulopathy. A case report.
  • BACKGROUND: An isolated cardiac metastasis from cervical carcinoma is very rare.
  • This report describes the unusual presentation in a patient diagnosed and successfully treated for stage IB squamous cell carcinoma of the cervix, presenting six months later with disease metastatic to the heart.
  • She had undergone successful surgical treatment of a stage IB squamous cell cervical carcinoma six months previously.
  • Computed tomography revealed a large mass in the right ventricle, confirmed by echocardiography.
  • Frozen section confirmed metastatic squamous cell carcinoma.
  • The patient was discharged with follow-up radiation and chemotherapy.
  • CONCLUSION: All women with myocardial abnormalities and a history of squamous cell carcinoma of the cervix should be suspected of developing a myocardial metastasis until proven otherwise.
  • [MeSH-major] Blood Coagulation Disorders / diagnosis. Carcinoma, Squamous Cell / secondary. Heart Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Echocardiography. Female. Humans. Treatment Outcome


25. Menell JH, Chi DS, Hann LE, Hricak H: The use of MRI in the diagnosis and management of a bulky cervical carcinoma. Gynecol Oncol; 2003 Jun;89(3):517-21
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of MRI in the diagnosis and management of a bulky cervical carcinoma.
  • BACKGROUND: In the treatment of gynecologic cancer, surgical planning depends on the site and extent of disease.
  • The evaluation of the origin of a large pelvic mass with combined pelvic examination and ultrasound is often adequate.
  • On speculum examination the cervix was not visible.
  • A large, mobile pelvic mass was palpated during physical examination.
  • Pelvic ultrasound revealed a large, cystic pelvic mass thought to be ovarian in origin.
  • Surgery for presumed ovarian carcinoma was planned.
  • Because a vaginal Pap smear revealed squamous-cell carcinoma, MRI was performed for further evaluation.
  • MRI demonstrated a blood distended uterus with a large cervical tumor obstructing the endocervical os.
  • Multiple biopsies of the cervix confirmed the diagnosis of a bulky Stage IIA squamous-cell carcinoma of the cervix.
  • The patient was subsequently treated with concomitant chemotherapy and radiation therapy.
  • Follow-up MRI demonstrated an excellent treatment response.
  • CONCLUSIONS: Magnetic resonance imaging, through multiplanar capabilities and high-contrast resolution, is a valuable tool that can assist the clinician in the evaluation, diagnosis, and management of challenging gynecologic malignancies.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12798721.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. el Omari-Alaoui H, Kebdani T, Benjaafar N, el Ghazi E, Erriahni H, el Gueddari BK: [Non-Hodgkin's lymphoma of the uterus: apropos of 4 cases and review of the literature]. Cancer Radiother; 2002 Feb;6(1):39-45
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This rarity explains of one part certain difficulties of the histological diagnosis and on the other hand the absence of a therapeutic strategy clearly established.
  • Histological diagnosis was confirmed by biopsy for the cervical location.
  • For the corpus location, it is study of the uterus after hysterectomy which retained the diagnosis of lymphoma.
  • The type of the lymphoma was low grade in two cases and high grade in the two other cases.
  • The treatment consisted of an association of chemotherapy and radiotherapy in both cases of lymphoma of the cervix and in a radical hysterectomy followed by chemotherapy for the two cases of lymphoma of the corpus.
  • Two patients are in disease free, the third patient presented a dissemination of the disease and the fourth patient presented a squamous cell carcinoma of the lung.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Biopsy. Cervix Uteri / pathology. Cyclophosphamide. Diagnosis, Differential. Doxorubicin. Female. Follow-Up Studies. Humans. Hysterectomy. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / radiotherapy. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, Large B-Cell, Diffuse / therapy. Middle Aged. Prednisone. Radiotherapy Dosage. Time Factors. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / therapy. Uterus / pathology. Vincristine

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11899679.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


27. Marnitz S, Köhler C, Füller J, Hinkelbein W, Schneider A: Uterus necrosis after radiochemotherapy in two patients with advanced cervical cancer. Strahlenther Onkol; 2006 Jan;182(1):45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Simultaneous platinum-based radiochemotherapy is the standard of care for patients with advanced or node-positive cancer of the uterine cervix.
  • A large body of literature concerning therapy-related acute and late morbidity is available.
  • Both patients were diagnosed with squamous cell cancer of the cervix FIGO stage IIB (T2b pN1 pM1 LYM G2) and FIGO IIIA (T3a pN1 M0 G2), respectively.
  • Patient #2 underwent 5 x 5 Gy brachytherapy covering the tumor.
  • Following chemoradiation, both patients developed pelvic pain and an elevation of C-reactive protein (CRP) in the presence of a normal leukocyte count.
  • CONCLUSION: In patients with persisting or incident pelvic pain, questionable findings in imaging techniques and/or elevated inflammation parameters following completion of chemoradiation for cervical cancer, differential diagnosis should include radiogenic necrosis of the uterus and other pelvic organs.
  • Laparoscopy is an ideal technique to exclude or confirm this diagnosis.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiation Injuries / etiology. Radiotherapy / adverse effects. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy. Uterus / pathology. Uterus / radiation effects
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Brachytherapy. Cervix Uteri / pathology. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Hysterectomy. Iridium Radioisotopes / therapeutic use. Laparoscopy. Middle Aged. Necrosis. Neoplasm Staging. Ovariectomy. Radiotherapy Dosage. Radiotherapy, Conformal. Time Factors


28. Thyagarajan MS, Dobson MJ, Biswas A: Case report: appearance of uterine cervical lymphoma on MRI: a case report and review of the literature. Br J Radiol; 2004 Jun;77(918):512-5
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the appearances on CT and MRI of a case of non-Hodgkin's lymphoma (NHL) of uterine cervix.
  • Clinically, the cervix was replaced by a huge ulcerating mass.
  • Biopsy showed malignant high grade B-cell NHL.
  • T(2) weighted MRI of the pelvis showed a 12 cm intermediate signal mass replacing the cervix, with infiltration of the vagina and left parametrium, and bilateral internal iliac lymphadenopathy.
  • The patient is in complete remission 7 months post chemotherapy, radiotherapy and stenting of biliary stricture.
  • The success of the cervical cancer screening programme has lead to a reduction in the number of cases of advanced cervical carcinoma and the presence of an unusually large homogeneous cervical tumour, with relatively scant necrosis should prompt suspicion of a less common histology such as NHL.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15151974.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 30
  •  go-up   go-down


29. Tan LT, Zahra M: Long-term survival and late toxicity after chemoradiotherapy for cervical cancer--the Addenbrooke's experience. Clin Oncol (R Coll Radiol); 2008 Jun;20(5):358-64
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To evaluate the long term cause-specific survival and late toxicity of chemoradiotherapy for carcinoma of the cervix treated outside research settings.
  • MATERIALS AND METHODS: Between May 1999 and April 2003, 74 patients with carcinoma of the cervix were treated with radical radiotherapy given concurrently with weekly cisplatin chemotherapy.
  • Three patients died during treatment, leaving 71 patients available for analysis of long-term survival and late toxicity of treatment.
  • In total, 56 patients (78.9%) received chemoradiotherapy as primary radical treatment.
  • Ten patients (14.1%) received chemoradiotherapy as adjuvant treatment after radical surgery.
  • The remaining five patients (7.0%) received chemoradiotherapy as salvage treatment for pelvic recurrences after previous surgery.
  • Forty-seven (66.2%) patients had squamous cell carcinomas, whereas 24 (33.8%) patients had adenocarcinomas.
  • The actuarial 5-year cause-specific survival for the 66 patients undergoing primary treatment (chemoradiotherapy+/-surgery) was 54.6%.
  • Of the 66 patients undergoing primary treatment, seven (10.6%) had persistent disease after chemoradiotherapy.
  • Of the 22 patients (33.3%) who relapsed >6 months after treatment, eight (36.4%) relapsed within the pelvis alone, 12 (54.5%) had metastatic disease alone, whereas two (9.1%) had both local and distant relapse.
  • Eight of 23 patients (34.8%) with adenocarcinomas developed metastatic disease compared with only six of 43 patients (14.0%) with squamous cell tumours.
  • There were no significant correlations between the incidence of serious late toxicity and disease stage, field arrangement, treatment volumes or postoperative radiotherapy.
  • CONCLUSIONS: Our study has shown that the addition of chemotherapy to radiotherapy for cervical cancer probably improves the survival of patients treated outside research settings, but the benefit may not be as large as that obtained in clinical trials and the risk of serious late toxicity is increased.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy / adverse effects. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / adverse effects. Female. Humans. Middle Aged. Platinum Compounds / administration & dosage. Platinum Compounds / adverse effects. Survival Analysis

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395427.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  •  go-up   go-down


30. Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H, Moxley M, Palefsky J, Sacks H, Burk RD, Gange SJ: Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst; 2004 Jul 21;96(14):1070-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women.
  • BACKGROUND: Women infected with human immunodeficiency virus (HIV) have an increased risk of persistent squamous intraepithelial lesions (SILs) of the cervix.
  • We assessed the association between use of highly active antiretroviral therapy (HAART) and regression of SIL in HIV-infected women enrolled in the Women's Interagency HIV Study, a large, multicenter, prospective cohort study.
  • Pap smears, CD4+ T-cell counts, and information regarding use of HAART were obtained every 6 months.
  • RESULTS: Of 312 women, 141 had lesions that regressed to normal cytology, with a median time to regression of 2.7 years.
  • Overall, the incidence of regression increased (P(trend) =.002) over time after HAART was introduced.
  • At incident SIL, median CD4+ T-cell counts were lower in women whose lesions did not regress than in women whose lesions regressed (230 versus 336 cells/microL; P<.01).
  • After HAART was introduced, the rate was 12.5% (95% CI = 9.9% to 15.1%) and was related to post-HAART CD4+ T-cell counts (P(trend) =.002).
  • CONCLUSIONS: HAART use was associated with increased regression of SIL among HIV-infected women, and among women who used HAART, increased CD4+ T-cell counts were associated with a greater likelihood of regression.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Antiretroviral Therapy, Highly Active. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. HIV Seropositivity / drug therapy. Papillomaviridae. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. CD4-Positive T-Lymphocytes. Female. Follow-Up Studies. Humans. Lymphocyte Count. Papanicolaou Test. Papillomavirus Infections / complications. Prospective Studies. Research Design. Treatment Outcome. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2004 Jul 21;96(14):1051-3 [15265960.001]
  • (PMID = 15265968.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCRR NIH HHS / RR / M01-RR00083; United States / NIAID NIH HHS / AI / U01-AI-31834; United States / NIAID NIH HHS / AI / U01-AI-34989; United States / NIAID NIH HHS / AI / U01-AI-34993; United States / NIAID NIH HHS / AI / U01-AI-34994; United States / NIAID NIH HHS / AI / U01-AI-35004; United States / NIAID NIH HHS / AI / U01-AI-42590; United States / NICHD NIH HHS / HD / U01-HD-32632
  • [Publication-type] Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


31. Caprara L, Monari F, De Bianchi PS, Amadori A, Bondi A: [ASCUS in screening]. Pathologica; 2001 Dec;93(6):645-50
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The significance and use of the cytological diagnosis "atypical squamous cells of undetermined significance" (ASCUS) remain a major problem in cervical cancer screening.
  • The present paper reports the prevalence of ASCUS in a large series of screening Pap smears from the Italian region of Emilia-Romagna.
  • The observed peak reflects the prevalence of (1) cytological changes closely associated with perimenopausal age and at least compatible with the ASCUS diagnosis, and (2) cytological abnormalities induced by hormone replacement therapy.
  • [MeSH-major] Cervix Uteri / pathology. Mass Screening. Papanicolaou Test. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Epithelial Cells / drug effects. Epithelial Cells / ultrastructure. Estrogens / pharmacology. False Positive Reactions. Female. Hormone Replacement Therapy. Humans. Italy. Menopause. Middle Aged. Neoplastic Stem Cells / ultrastructure. Progesterone / pharmacology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


32. Manchana T, Ittiwut C, Mutirangura A, Kavanagh JJ: Targeted therapies for rare gynaecological cancers. Lancet Oncol; 2010 Jul;11(7):685-93
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies for rare gynaecological cancers.
  • Some gynaecological cancers are uncommon, such as sex cord-stromal tumours, malignant germ-cell tumours, vulvar carcinoma, melanoma of the female genital tract, clear-cell carcinoma of the ovary and endometrium, neuroendocrine tumours of the cervix, and gestational trophoblastic neoplasia.
  • Despite aggressive treatment, some cancers recur or respond poorly to therapy.
  • Comprehensive knowledge of the molecular biology of each cancer might help with development of novel treatments that maximise efficacy and minimise toxic effects.
  • Targeted therapy is a new treatment strategy that has been investigated in various tumours in clinical and laboratory settings.
  • Since these cancers are rare and large clinical trials are difficult to do, molecular biological techniques might allow rapid proof-of-principle experiments in few patients.
  • Novel targeted agents either alone or in combination with other treatments offer promising therapeutic options.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems / trends. Genital Neoplasms, Female / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Female. Gestational Trophoblastic Disease / drug therapy. Humans. Melanoma / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy. Neuroendocrine Tumors / drug therapy. Pregnancy. Sex Cord-Gonadal Stromal Tumors / drug therapy. Vulvar Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20362508.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 77
  •  go-up   go-down


33. Narayan K, van Dyk S, Bernshaw D, Rajasooriyar C, Kondalsamy-Chennakesavan S: Comparative study of LDR (Manchester system) and HDR image-guided conformal brachytherapy of cervical cancer: patterns of failure, late complications, and survival. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1529-35
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: A retrospective comparative study of 217 advanced cervix cancer patients was conducted; 90 of these patients received LDR and 127 received HDRc brachytherapy.
  • Sixty-eight percent (87/127) of patients treated by HDRc remained asymptomatic, whereas 42% (38/90) of patients were asymptomatic from the bowel and bladder symptoms after treatment with LDR.
  • The 5-year OS rate was 60% (SE = 4%).
  • The 5-year failure-free survival rate was 55% (SE = 3%).
  • CONCLUSIONS: Image-guided HDRc planning led to a large decrease in late radiation effects in patients treated by HDRc.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy / methods. Female. Humans. Middle Aged. Radiotherapy Dosage. Radiotherapy, Conformal / adverse effects. Radiotherapy, Conformal / methods. Radiotherapy, Conformal / mortality. Retrospective Studies. Treatment Failure. Young Adult

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473780.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Glava-Obrovac L, Karner I, Pavlak M, Radacić M, Kasnar-Samprec J, Zinić B: Synthesis and antitumor activity of 5-bromo-1-mesyluracil. Nucleosides Nucleotides Nucleic Acids; 2005;24(5-7):557-69
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large-scale preparation of 5-bromo-1-mesyluracil (BMsU) 4 has been optimized.
  • The purpose of this study was to elucidate the effects of BMsU on the biosynthetic activity of tumor cell enzymes involved in DNA, RNA and protein syntheses, and in de novo and salvage pyrimidine and purine syntheses.
  • Investigations were performed in vitro on human cervix carcinoma cells (HeLa).
  • BMsU displayed inhibitory effects on DNA and RNA syntheses in HeLa cells after 24 h of treatment.
  • The model used in investigations was a mouse anaplastic mammary carcinoma transplanted into the thigh of the right leg of CBA mice.
  • Significant reduction in tumor growth time was achieved with BmsU administered at a dose of 50 mg/kg.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Neoplasms / drug therapy. Sulfones / pharmacology. Uracil / analogs & derivatives. Uracil / chemical synthesis. Uracil / pharmacology
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. DNA / chemistry. Female. HeLa Cells. Humans. In Vitro Techniques. Male. Mice. Mice, Inbred CBA. Models, Chemical. Neoplasm Transplantation. Purines / chemistry. Pyrimidines / chemistry. RNA / chemistry. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247989.001).
  • [ISSN] 1525-7770
  • [Journal-full-title] Nucleosides, nucleotides & nucleic acids
  • [ISO-abbreviation] Nucleosides Nucleotides Nucleic Acids
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-bromo-1-mesyluracil; 0 / Antineoplastic Agents; 0 / Purines; 0 / Pyrimidines; 0 / Sulfones; 56HH86ZVCT / Uracil; 63231-63-0 / RNA; 9007-49-2 / DNA
  •  go-up   go-down


35. Righetti PG, Castagna A, Antonucci F, Piubelli C, Cecconi D, Campostrini N, Rustichelli C, Antonioli P, Zanusso G, Monaco S, Lomas L, Boschetti E: Proteome analysis in the clinical chemistry laboratory: myth or reality? Clin Chim Acta; 2005 Jul 24;357(2):123-39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS AND CONCLUSIONS: In the field of cancer research, it is here shown that stathmin (Op18) becomes heavily phosphorylated in cancerous mantle cell lymphomas and that the progression of the disease can be followed by the progression of phosphorylation of Op18 and by the appearance of additional phosphorylated spots.
  • Also chemoresistance of different tumors has been evaluated via 2D-PAGE through quantitative, differential proteomics: among up- and down-regulated proteins in a human cervix squamous cell carcinoma cell line (A431), rendered resistant to cisplatin, one particular protein was found to appear in large quantities by de novo synthesis: 14-3-3, a protein known to impart resistance to apoptosis to cells.
  • In the field of brain disorders, we could set up an easy test for detecting pathological prions in sporadic Creutzfeldt-Jakob disease (sCJD), by simply searching for those pathological forms in the olfactory mucosa (up to this finding, diagnosis could only be confirmed post-mortem).
  • By this test, sCJD could be differentiated from all the other degenerative dementias, which are 14-3-3 negative (in sCJD, the rapid and massive brain cell damage releases large quantities of 14-3-3 in the cerebrospinal fluid).
  • [MeSH-minor] Animals. Brain Diseases / metabolism. Humans. Neoplasms / drug therapy. Neoplasms / metabolism


36. Markopoulos MC, Lagadas AA, Alexandrou P, Giannakopoulos KC, Polyzos A: Prolonged disease free survival with aggressive adjuvant chemotherapy in a case of large cell neuroendocrine carcinoma of the uterine cervix. J BUON; 2009 Apr-Jun;14(2):322-3
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged disease free survival with aggressive adjuvant chemotherapy in a case of large cell neuroendocrine carcinoma of the uterine cervix.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / mortality. Carcinoma, Neuroendocrine / mortality. Neoplasms, Multiple Primary / mortality. Uterine Cervical Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650188.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement